This article was originally published in Start Up
Neosil Inc. intends to develop NCEs for unmet needs in dermatology. Something of a rarity these days, Neosil intends to become a real pharmaceutical company, taking selected products through regulatory approval to the US market by itself.
You may also be interested in...
Ever hungry for new investment opportunities, VCs are now backing start-ups developing novel dermatology products for both medical and cosmetic conditions. These aren't your typical "derm" companies. Not content to invent new delivery vectors for existing medicines or reformulate them into more patient friendly creams, these fledgling companies are trying to develop new chemical entities based on novel skin biology.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)